Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Com…

Data presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, ...
Taiwan News

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with ...

In preclinical experiments, the combination of Trastuzumab PH1 + anti-PD1 outperforms the combination of Kadcyla® + anti-PD1 with a statistically significantly greater rate of Complete Responses (74% ...

Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day

Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for ...
Targeted Oncology

FDA Fast Tracks Bispecific ADC AVZO-1418 for EGFR-Mutated Pretreated NSCLC

The FDA has granted fast track designation to the EGFR/HER3 bispecific antibody-drug conjugate (ADC) AVZO-1418 for treatment ...
EurekAlert!

Antibody-drug conjugates emerge as potent anti-tumor agents for gynecological cancers

Gynecological cancers remain a major threat to women's health, with traditional therapies often having limited effect and ...
CNET

Sick of Skyrocketing Streaming Costs? How to Cancel the Services You Don't Need

Jen Karner has spent the last 10 years covering technology, streaming services, video games, while working behind the scenes as an editor for her teams. She's also the author of the award winning ...